 |
29 Products |  |
56 Diseases | | 29 Products |
|
145 Trials |  |
7552 News |  |
| «12...7891011121314151617...99100» |
- | Goofice (elobixibat) / Ipsen
New trial: Comparison of Bowel Preparation Using 2 Liter Polyethylene Glycol Regimen Plus Elobixibat Versus 4-Liter Polyethylene Glycol Regimen (clinicaltrials.gov) - May 30, 2024
P=N/A, N=360, Not yet recruiting, Sponsor: Rajavithi Hospital
- Actemra IV (tocilizumab) / Roche, JW Pharma
RATE OF THERAPEUTIC FAILURES PRESENTED AFTER SWITCHING FROM TOCILIZUMAB TO ANOTHER BIOLOGICALS IN PATIENTS WITH RHEUMATOID ARTHRITIS FACING A SITUATION OF SUPPLY SHORTAGE () - May 29, 2024 - Abstract #EULAR2024EULAR_4463;
The data from this study show that the most effective molecule in real life after switching of post-TCZ is Rituximab. On the other hand, up to a third of patients return to treatment with TCZ due to failure to switch to the first biologic post-TCZ.
- REAL WORLD DATA FROM A SINGLE CENTER: SURVIVAL RATES OF TNFi AS FIRST AND SECOND LINE TREATMENT IN PATIENTS WITH PSORIATIC ARTHRITIS () - May 29, 2024 - Abstract #EULAR2024EULAR_4227;
TNFi display good overall survival rates as first line treatment among PsA with inadequate response to cDMARDs. Female gender and peripheral involvement are independent risk factors for early secondary inefficacy to first TNFi.
- Tremfya (guselkumab) / J&J
COMPARISON OF ON-LABEL TREATMENT PERSISTENCE IN REAL-WORLD PATIENTS WITH PSORIATIC ARTHRITIS RECEIVING GUSELKUMAB VERSUS SUBCUTANEOUS TNF INHIBITORS () - May 29, 2024 - Abstract #EULAR2024EULAR_4174;
Adults with PsA newly initiated on guselkumab or the first observed SC TNFi (i.e., adalimumab, certolizumab pegol, etanercept, or SC golimumab) between 7/14/2020 and 3/31/2022 were selected from the IQVIA TM Health Plan Claims Data. This real-world study assessing treatment persistence in PsA using administrative claims data demonstrated that guselkumab was associated with significantly longer on-label persistence through 12 months versus SC TNFi.
- INFLAMMATORY DISEASES AND RISK OF NEOPLASIA: IS IT THE TREATMENT OR THE DISEASE IN SINE? DATA ON THE MANAGEMENT OF INFLAMMATION IN CASE OF COEXISTENCE WITH MALIGNANCY () - May 29, 2024 - Abstract #EULAR2024EULAR_4000;
It appears that the risk of relapse of inflammation in patients receiving bDMARDs is high. Although these agents appear to be safe in patients with a history of cancer (without evidence of tumor activity), additional data is needed to determine the correct timing of restarting the treatment.
- DISEASE FLARES IN PATIENTS WITH RHEUMATOID ARTHRITIS FOLLOWING COVID-19 BREAKTHROUGH INFECTION: RESULT FROM COVAD E-SURVEY STUDY () - May 29, 2024 - Abstract #EULAR2024EULAR_3841;
Although these agents appear to be safe in patients with a history of cancer (without evidence of tumor activity), additional data is needed to determine the correct timing of restarting the treatment. Younger age (odds ratio (OR): 0.98, 95% CI: 0.96
- WHAT IS THE TRUTH? - COMPARISON OF REACTIONS AND ADVERSE EVENTS BETWEEN JAK INHIBITORS AND ANTI-TNFS - REAL LIFE EXPERIENCE () - May 29, 2024 - Abstract #EULAR2024EULAR_3757;
No major cardiovascular events or thrombotic events were found in a great population of patients using JAKs inhibitors in recent two years. Larger studies are required in the Latin American population to confirm these results.
- VIRAL INFECTIONS AMONG PATIENTS RECEIVING BIOLOGICS FOR RHEUMATIC DISEASES () - May 29, 2024 - Abstract #EULAR2024EULAR_3673;
Biological therapies, especially TNF alpha inhibitors, may lead to an increased risk of viral infections. These infections were reported in 6% of our patients.
- Humira (adalimumab) / AbbVie
NON-MEDICAL SWITCH OF BIOLOGIC DRUGS IN PATIENTS WITH RHEUMATIC DISEASE () - May 29, 2024 - Abstract #EULAR2024EULAR_3572;
Patients with SpA were the most affected. Golimumab has the preferred application device.
- Cimzia (certolizumab pegol) / Astellas, UCB
DO HIGH RHEUMATOID FACTOR LEVELS IMPACT RESPONSE TO CERTOLIZUMAB PEGOL IN PATIENTS WITH INADEQUATELY CONTROLLED RHEUMATOID ARTHRITIS? A POST HOC ANALYSIS OF THE PHASE 3B REALISTIC TRIAL () - May 29, 2024 - Abstract #EULAR2024EULAR_3472;
P3
In contrast, pts with RA and high RF levels who were treated with CZP had similar clinical responses to those with low RF levels, indicating that RF does not influence the response to CZP. These data expand previous notions 5 to a TNFi-IR population.
- Orencia (abatacept) / BMS, Actemra IV (tocilizumab) / Roche, JW Pharma, Cimzia (certolizumab pegol) / Astellas, UCB
CIRCULATING ADIPOKINES AND RESPONSE TO TREATMENT IN EARLY RHEUMATOID ARTHRITIS () - May 29, 2024 - Abstract #EULAR2024EULAR_3440;
Baseline adiponectin, leptin, and resistin levels are not associated with the likelihood of achieving CDAI remission over 48 weeks in this large trial of first-line treatments in early RA. Our results underscore the importance of adjusting for confounders when studying the effects of adipokines on RA outcomes, as circulating adipokine levels are highly dependent on other factors, such as BMI and sex.
- FOLLOW-UP DATA ON DRUG-INDUCED LUPUS CASES DURING TNF-ALPHA INHIBITOR TREATMENT () - May 29, 2024 - Abstract #EULAR2024EULAR_3249;
In patients who develop positive ds-DNA during the use of TNF inhibitors and exhibit mild symptoms, close monitoring while continuing the TNF inhibitor appears to be safe. Larger-scale studies are needed to establish a diagnosis, treatment, and follow-up algorithm in this field.
- Enbrel (etanercept) / Pfizer, Amgen, Cimzia (certolizumab pegol) / Astellas, UCB
EFFECTS OF ONE-YEAR ANTI-TNF-? THERAPY ON NATURAL AUTOANTIBODIES IN ASSOCIATION WITH VASCULAR PATHOPHYSIOLOGY IN RHEUMATOID ARTHRITIS AND ANKYLOSING SPONDYLITIS () - May 29, 2024 - Abstract #EULAR2024EULAR_3007;
Biologic therapy also increased anti-CS and anti-TOPO-F4 levels. The production of nAAbs was variably associated with, among other parameters, CRP, disease activity and vascular pathophysiology suggesting that nAAbs might form a link between arthritis and atherosclerosis.
- Cimzia (certolizumab pegol) / Astellas, UCB
EFFECTIVENESS OF CERTOLIZUMAB ON FEMALE PATIENTS WITH CHRONIC ARTHRITIS ACCORDING TO THE FERTILITY OR MENOPAUSAL AGE. ANALYSIS FROM THE APULIAN BIOPURE REGISTRY () - May 29, 2024 - Abstract #EULAR2024EULAR_3006;
Figure 1. Table 1.
- PATTERNS OF bDMARDs PRESCRIPTION IN SPONDYLOARTHRITIS AFTER FIRST TNFi FAILURE () - May 29, 2024 - Abstract #EULAR2024EULAR_2902;
Since 2017, novel targets have emerged, and IL-17i have showed efficacy in controlling disease activity. In our study, 50% of the patients started the 2 nd line bDMARD before 2017, so, as expected, most patients were TNFi cyclers.
- Cimzia (certolizumab pegol) / Astellas, UCB
EFFICACY OF CERTOLIZUMAB PEGOL IN PREVENTING ANTERIOR UVEITIS FLARES COMPARED WITH STANDARD NON-BIOLOGIC TREATMENT: A MATCHED CONTROL STUDY IN HIGH-RISK PATIENTS WITH AXIAL SPONDYLOARTHRITIS () - May 29, 2024 - Abstract #EULAR2024EULAR_2873;
P4
In our study, 50% of the patients started the 2 nd line bDMARD before 2017, so, as expected, most patients were TNFi cyclers. This matched control study supports the benefit of CZP over standard non-biologic treatment in reducing anterior uveitis flares among high-risk patients with axSpA, highlighting its potential as a promising therapeutic option in managing this debilitating ocular manifestation in axSpA.
- Cosentyx (secukinumab) / Novartis, Cimzia (certolizumab pegol) / Astellas, UCB
DRUG SURVIVAL AND PREDICTOR FACTORS OF DISCONTINUATION IN AXIAL SPONDYLOARTHRITIS PATIENTS RECEIVING CERTOLIZUMAB AND SECUKINUMAB () - May 29, 2024 - Abstract #EULAR2024EULAR_2868;
Notably, gender differences in drug discontinuation were observed, with females showing divergent retention patterns for the two drugs. These findings highlight the need for gender-specific considerations in AxSpA treatment strategies.
- || Rekovelle (follitropin delta) / Ferring
Review, Journal: The pregnancy outcomes among women receiving individualized algorithm dosing with follitropin delta: a systematic review of randomized controlled trials. (Pubmed Central) - May 29, 2024
The personalized individualized-based algorithm dosing with follitropin delta is non-inferior to conventional follitropin alfa or follitropin beta. It is as effective in promoting a similar response in women without significant comparable adverse effects.
- || PRIM-DJ2727 / UT Health Science Center, Vowst (fecal microbiota spores, live-brpk) / Seres Therap, Nestle, Rebyota (fecal microbiota, live-jslm) / Ferring
Review, Journal: Microbiota restoration therapies for recurrent Clostridioides difficile infection reach an important new milestone. (Pubmed Central) - May 27, 2024
It is as effective in promoting a similar response in women without significant comparable adverse effects. PubMed was reviewed on 1 October 2023, for all papers published concerning the current Food and Drug Administration allowance of the use of fecal microbiota transplantation (FMT) and the studies that led to the licensure of RBX2660 (REBYOTA
- || Rebyota (fecal microbiota, live-jslm) / Ferring
Retrospective data, Review, Journal: Efficacy of Fecal Microbiota (REBYOTA) in Recurrent Clostridium difficile Infections: A Systematic Review and Meta-Analysis. (Pubmed Central) - May 27, 2024
Patients who received RBX2660 (REBYOTA) were significantly less likely to have recurrent Clostridium difficile than controls eight weeks after treatment. This effect is seen in both those who got one or two doses of RBX2660 (REBYOTA), although the FDA currently approves one dose.
- | Cervidil (dinoprostone) / Ferring
Retrospective data, Journal: A model to predict delivery time following induction of labor at term with a dinoprostone vaginal insert: a retrospective study. (Pubmed Central) - May 26, 2024
This effect is seen in both those who got one or two doses of RBX2660 (REBYOTA), although the FDA currently approves one dose. Our findings may help obstetricians estimate the DT before placing a dinoprostone insert, which may improve patient management in busy maternity wards and minimize potential risks.
- || Review, Journal: Biologics for Psoriasis. (Pubmed Central) - May 26, 2024
IL-23 inhibitors had lowest rates of short-term and long-term adverse events and most favorable long-term risk-benefit profile compared to IL-17, IL-12/23, and TNF-? inhibitors.
- | Retrospective data, Journal, HEOR: Treatment Discontinuation in Patients with Psoriasis Treated with Biologics: A Retrospective Analysis of German Health Claims Data. (Pubmed Central) - May 24, 2024
inhibitors. Further research should explore reasons leading to treatment discontinuation in order to support treatment choices for patients with moderate-to-severe psoriasis.
- || VE303 / Vedanta Biosci, Vowst (fecal microbiota spores, live-brpk) / Seres Therap, Nestle, Rebyota (fecal microbiota, live-jslm) / Ferring
Review, Journal: A Comparison of Currently Available and Investigational Fecal Microbiota Transplant Products for Recurrent Clostridioides difficile Infection. (Pubmed Central) - May 24, 2024
This article will be an in-depth review of five microbiome therapeutic products that are either under investigation or currently commercially available: Rebyota (fecal microbiota, live-jslm, formerly RBX2660), Vowst (fecal microbiota spores, live-brpk, formerly SER109), VE303, CP101, and RBX7455. Included in this review is a comparison of the products' composition and dosage forms, available safety and efficacy data, and investigational status.
- ||||| Rekovelle (follitropin delta) / Ferring
Enrollment closed: ADAPT-1: A Trial to Compare the Ovarian Response of REKOVELLE and GONAL-F in Conventional Dosing in Women Undergoing Controlled Ovarian Stimulation (clinicaltrials.gov) - May 22, 2024
P3, N=302, Active, not recruiting, Sponsor: Ferring Pharmaceuticals
Included in this review is a comparison of the products' composition and dosage forms, available safety and efficacy data, and investigational status. Recruiting --> Active, not recruiting
- ||| Journal, Adverse events, Real-world evidence, Real-world: Neurological disorders following the use of tumor necrosis factor-? inhibitors in inflammatory bowel disease patients: a real-world pharmacovigilance analysis. (Pubmed Central) - May 21, 2024
However, there were no signals among neurological AEs for golimumab. Neurological signals were detected for TNFi use, indicating that the risk of neurological AEs requires additional attention in clinical use of TNFis.
- || olamkicept (FE999301) / Ferring
Clinical, P1 data, PK/PD data, Clinical Trial,Phase I, Journal: Safety, tolerability, and pharmacokinetics of single- and multiple-ascending doses of olamkicept: Results from randomized, placebo-controlled, first-in-human phase I trials. (Pubmed Central) - May 21, 2024
Complete target engagement (inhibition of phosphorylation of signal transducer and activator of transcription-3) was achieved in blood around or above olamkicept serum concentrations of 1-5 ?g/mL. Overall, these results suggest that olamkicept is safe and well-tolerated in healthy subjects and patients with CD after single intravenous/SC and multiple intravenous administrations.
- || PK/PD data, Review: Pharmacokinetics of Monoclonal Antibodies Throughout Pregnancy: A Systematic Literature Review. (Pubmed Central) - May 20, 2024
Available information suggests that the anatomical and physiological changes throughout pregnancy may have meaningful effects on the PK of mAbs. For most mAbs (not IFX), modestly higher dosing (per mg) maybe needed during pregnancy to sustain a similar serum exposure compared to pre-pregnancy.
- | Journal: Rheumatoid factor titers, but not Fc fragments, may be strongly associated with drug survival of anti-TNF agents in patients with rheumatoid arthritis. (Pubmed Central) - May 17, 2024
For most mAbs (not IFX), modestly higher dosing (per mg) maybe needed during pregnancy to sustain a similar serum exposure compared to pre-pregnancy. Our results suggest that compared to the Fc fragment, RF titers were the more important risk factor in survival of anti-TNF drugs.
- | Journal: Efficacy and safety of pharmacological treatment of psoriatic arthritis: a systematic literature research informing the 2023 update of the EULAR recommendations for the management of psoriatic arthritis. (Pubmed Central) - May 15, 2024
Our results suggest that compared to the Fc fragment, RF titers were the more important risk factor in survival of anti-TNF drugs. The results of this SLR informed the task force responsible for the 2023 update of the European Alliance of Associations for Rheumatology recommendations for pharmacological management of PsA.
- | Journal: Vaccination Recommendations for Adults Receiving Biologics and Oral Therapies for Psoriasis and Psoriatic Arthritis: Delphi Consensus from the Medical Board of the National Psoriasis Foundation. (Pubmed Central) - May 15, 2024
The results of this SLR informed the task force responsible for the 2023 update of the European Alliance of Associations for Rheumatology recommendations for pharmacological management of PsA. Interruption of antipsoriatic oral and biologic therapies is generally not necessary for
- || Cosentyx (secukinumab) / Novartis
Review, Journal: New-Onset, Treatment-Resistant Inflammatory Bowel Disease after Administration of Secukinumab for Plaque Psoriasis: A Case Report and Review of the Existing Literature. (Pubmed Central) - May 13, 2024
Interestingly, our case is a "treatment-resistant" one since treatment with a biologic disease-modifying drug (bDMARD) usually leads to disease remission. As such, it is crucial to investigate the special characteristics of this clinical entity.
- | Cimzia (certolizumab pegol) / Astellas, UCB
Retrospective data, Journal: Certolizumab pegol effectiveness, survival and safety in patients with psoriasis: A multicenter retrospective analysis in daily clinical practice by the Spanish Psoriasis Group. (Pubmed Central) - May 13, 2024
Certolizumab consistently showed high effectiveness and drug survival rates in this real-life cohort. The safety demonstrated in clinical trials during pregnancy and lactation seems to be confirmed in clinical practice.
- || Review, Journal: Clostridioides Difficile: A Concise Review of Best Practices and Updates. (Pubmed Central) - May 10, 2024
In 2021, the Infectious Diseases Society of America/Society for Healthcare Epidemiology of America (IDSA/SHEA) shifted its preference for initial treatment to fidaxomicin over vancomycin and metronidazole due to its lower recurrence rate...There are new developments on the frontiers of fecal microbiota therapies, with RBX2660 and SER-109 approved recently by the FDA for prevention, with other microbiome-based therapies in various development and clinical trials. This review offers providers an updated and practical guide for CDI management.
- Oncofid-P (paclitaxel-hyaluronic acid conjugate) / Fidia Farmaceutici
A PHASE III, SINGLE-ARM STUDY TO EVALUATE THE EFFICACYAND SAFETY OF PACLITAXEL-HYALURONIC ACID CONJUGATE ADMINISTERED INTRAVESICALLY TO PATIENTS WITH BCG-UNRESPONSIVE CARCINOMA IN SITU OF THE BLADDER WITH OR WITHOUT TA-T1 PAPILLARY DISEASE (ORION-BC STUDY) () - May 8, 2024 - Abstract #AUA2024AUA_4230;
P3
InJanuary 2020, the Food and Drug Administration (FDA) approvedpembrolizumab (Keytruda, Merck&Co) for the systemic treatment ofpatients with BCGeunresponsive, high-risk NMIBC with CIS, with orwithout papillary tumors, who are ineligible for or choose not to undergoRC...In 2022 intravesical Adstiladrin (Ferring), which acts bystimulating immune responses, was approved by the FDA based onefficacy on 50 subjects out of 107 enrolled [51% (95% CI: 41%, 61%)]who experienced a CR at the first disease assessment three monthsafter initial treatment...gemcitabine and docetaxel, Milbar 2017)...Up to 146 patients will be enrolled: up to now 9 patientswere enrolled and treated. The first DSMB meeting is scheduled end of January 2024.
- | Xtandi (enzalutamide) / Pfizer, Astellas
Trial completion date: Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer (clinicaltrials.gov) - May 6, 2024
P2, N=19, Active, not recruiting, Sponsor: University of Colorado, Denver
The first DSMB meeting is scheduled end of January 2024. Trial completion date: Apr 2024 --> Apr 2025
- Firmagon (degarelix) / Astellas, Ferring
KNDy Neurons and the Control of the Gonadotropic Axis in Midgestation Fetal Sheep (ENDOExpo PosterArea - BCEC) - May 5, 2024 - Abstract #ENDO2024ENDO_254;
Trial completion date: Apr 2024 --> Apr 2025 Conversely, chemical castration of midgestation male fetuses by treatment with the GnRH antagonist degarelix from day 60
- | Firmagon (degarelix) / Astellas, Ferring, Orgovyx (relugolix) / Intas, Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Pharma, Pfizer
New P3 trial: ADT and SBRT vs SBRT Alone for Unfavorable Intermediate Risk Prostate Cancer (clinicaltrials.gov) - May 3, 2024
P3, N=392, Recruiting, Sponsor: NYU Langone Health
- Biologic and Small-Molecule Treatments in Scalp and Nail Psoriasis () - May 2, 2024 - Abstract #INDERCOS2024INDERCOS_40;
6 Roflumilast foam 0.3% was evaluated in a phase II trial in patients with scalp and body psoriasis...A total of 68 studies on 15 nail psoriasis targeted therapeutic agents which are TNF-alpha inhibitors (adalimumab, infliximab, etanercept, certolizumab, golimumab), IL-17 inhibitors (ixekizumab, brodalumab, secukinumab), IL-12/23 inhibitors (ustekinumab), IL-23 inhibitors (guselkumab, risankizumab, tildrakizumab), PDE-4 inhibitors (apremilast), and JAK inhibitors (tofacitinib)...9 The therapy choices in NP have increased with the approval of new biologics and small molecules such as brodalumab, risankizumab, tildrakizumab, bimekizumab, and deucravacitinib...However, most RCTs assessing SP and NP outcomes are subgroup or post-hoc analyses of patients with scalp and nail involvement among larger PsO/PsA populations. RCTs particularly focusing on SP and NP are needed for better evaluation of efficacy and safety results of biologic and small molecule inhibitors.
- | Firmagon (degarelix) / Astellas, Ferring
Journal: Effects of Follicle Stimulating Hormone on Energy Balance and Tissue Metabolic Health After Loss of Ovarian Function. (Pubmed Central) - Apr 30, 2024
Female Wistar rats were ovariectomized and given the gonadotropin releasing hormone (GnRH) antagonist degarelix to suppress FSH production...Additionally, rats administered FSH had reduced liver triglyceride concentration (p<0.001), which correlated with FSH-induced changes at the transcriptomic level. While not appearing to modulate energy balance after loss of ovarian function in rats, FSH may still impart tissue-specific effects in the liver and white adipose tissue that might affect the metabolic health of those organs.
- | Adstiladrin (nadofaragene firadenovec-vncg) / Ferring
New P4 trial: ABLE-42: A Trial to Evaluate Efficacy of Reinduction With Nadofaragene Firadenovec in Subjects With CIS (clinicaltrials.gov) - Apr 30, 2024
P4, N=25, Not yet recruiting, Sponsor: Ferring Pharmaceuticals
- | Firmagon (degarelix) / Astellas, Ferring
Enrollment open, Trial initiation date, Trial primary completion date: NeoADT-TULSA: Neoadjuvant ADT with TULSA in the Treatment of Intermediate Risk Prostate Cancer (clinicaltrials.gov) - Apr 24, 2024
P1, N=15, Recruiting, Sponsor: Turku University Hospital
While not appearing to modulate energy balance after loss of ovarian function in rats, FSH may still impart tissue-specific effects in the liver and white adipose tissue that might affect the metabolic health of those organs. Not yet recruiting --> Recruiting | Initiation date: Jul 2023 --> Oct 2023 | Trial primary completion date: Jul 2025 --> Dec 2025
- Firmagon (degarelix) / Astellas, Ferring, Orgovyx (relugolix) / Intas, Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Pharma, Pfizer
Evaluation of persistence and adherence for oral and injectable androgen deprivation therapies (ADT) in United States (US) patients with prostate cancer (PC). () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6812;
Despite differences in mode of administration, findings indicate that persistence and adherence are similar in pts with PC treated with REL and GnRH agonists while higher than those treated with DEG. Future research is needed to understand the factors associated with persistence and adherence.
- Adstiladrin (nadofaragene firadenovec-vncg) / Ferring
Cost effectiveness analysis of nadofaragene firadenovec for the treatment of high-risk, bacillus Calmette-Guerin (Hall A; Poster Bd #: 293) - Apr 24, 2024 - Abstract #ASCO2024ASCO_1763;
P2, P3
Future research is needed to understand the factors associated with persistence and adherence. The analysis suggests that nadofaragene firadenovec is cost-effective compared to pembrolizumab for the treatment of high-risk, BCG unresponsive NMIBC with CIS
- Firmagon (degarelix) / Astellas, Ferring, Verzenio (abemaciclib) / Eli Lilly
ETHAN: A phase II study comparing different endocrine therapies for male breast cancer. (Hall A; Poster Bd #: 213b) - Apr 24, 2024 - Abstract #ASCO2024ASCO_1360;
P2
Tumor tissue will be collected for correlative analyses. The study opened to enrollment at Dana-Farber in October 2023, and additional sites will open in 2024.
- | Firmagon (degarelix) / Astellas, Ferring
Clinical Trial,Phase IV, Journal: Relationship between circulating FSH levels and body composition and bone health in patients with prostate cancer who undergo androgen deprivation therapy: The BLADE study. (Pubmed Central) - Apr 24, 2024
P4
All patients underwent administration of the luteinizing hormone-releasing hormone antagonist degarelix...The funder had no role in design and conduct of the study, collection, management, analysis, and interpretation of the data and in preparation, review, or approval of the manuscript. clinicalTrials.gov NCT03202381, EudraCT Number 2016-004210-10.
- || Opdivo (nivolumab) / Ono Pharma, BMS
Enrollment closed: Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors (clinicaltrials.gov) - Apr 24, 2024
P2, N=60, Active, not recruiting, Sponsor: Xiao X. Wei, MD
clinicalTrials.gov NCT03202381, EudraCT Number 2016-004210-10. Recruiting --> Active, not recruiting
- |||| Xtandi (enzalutamide) / Pfizer, Astellas
Trial completion date, Trial primary completion date, HEOR, Real-world evidence: Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland (clinicaltrials.gov) - Apr 24, 2024
P=N/A, N=1, Completed, Sponsor: Pfizer
Recruiting --> Active, not recruiting Trial completion date: Jun 2023 --> Apr 2024 | Trial primary completion date: Jun 2023 --> Apr 2024
- || Imaavy (nipocalimab-aahu) / J&J
Enrollment closed: DAISY: A Study to Evaluate the Nipocalimab and Certolizumab Combination Therapy in Participants With Active Rheumatoid Arthritis (clinicaltrials.gov) - Apr 23, 2024
P2, N=104, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
Trial completion date: Jun 2023 --> Apr 2024 | Trial primary completion date: Jun 2023 --> Apr 2024 Recruiting --> Active, not recruiting
- | Bravelle (urofollitropin) / Ferring
Journal: Clinical efficacy of Xuanju compound capsule combined with urofollitropin in the treatment of patients with idiopathic oligoasthenozoospermia (Pubmed Central) - Apr 23, 2024
Recruiting --> Active, not recruiting Xuanju compound capsule combined with urofollitropin tablets could significantly improve the semen quality, up-regulate the testosterone levels and T/E2 ratio in patients with idiopathic oligoasthenozoospermia.